ClinicalTrials.Veeva

Menu
U

Universitätsklinikum Jena | KIM II Häma/Onko - Studienzentrale KIM II

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Atezolizumab
Guselkumab
Ruxolitinib
Empagliflozin
Golimumab
Bevacizumab
Imatinib
Azacitidine
Aspirin
Dexamethasone

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

39 of 173 total trials

A Prospective Multicenter Phase 2 Study of the Chemotherapy-Free Combination of the Intravenous Phosphatidylinositol-3-Kinase (PI3K) Inhibitor Copanlisib in Combination With Obinutuzumab in Patients With Previously Untreated Follicular Lymphoma (FL) and a High Tumor Burden (Alternative-C)

The Alternative-C Trial is a prospective, multicenter Phase 2 Study to evaluate the efficacy of the chemotherapy-free combination of copanlisib and o...

Active, not recruiting
Follicular Lymphoma
Drug: Obinutuzumab
Drug: Copanlisib

This randomized controlled trial will outline the advantages and disadvantages of the subcutaneous implantable cardioverter defibrillator (ICD) compa...

Active, not recruiting
Ventricular Arrhythmias
Device: Implantation of subcutaneous ICD
Device: Implantation of transvenous ICD

This study is open to adults aged 18 and older or above legal age who have systemic sclerosis. People can participate if they have a specific subtype...

Enrolling
Scleroderma, Systemic
Drug: Placebo
Drug: Avenciguat (BI 685509)

The purpose of this study is to evaluate the efficacy of JNJ-78934804 at Week 48 compared to guselkumab and golimumab.

Active, not recruiting
Crohn's Disease
Biological: JNJ-78934804
Biological: Golimumab

The purpose of this study is to evaluate the efficacy and safety of JNJ-78934804 as compared to guselkumab and golimumab in participants with moderat...

Active, not recruiting
Colitis, Ulcerative
Biological: JNJ-78934804
Drug: Placebo

This is a multi-center study to compare the efficacy and safety of itolizumab versus placebo as first-line therapy for subjects with Grade III-IV aGV...

Enrolling
aGVHD
Graft Versus Host Disease
Drug: EQ001 Placebo
Biological: Itolizumab

The purpose of this study is to evaluate the safety, tolerability, and efficacy of mavacamten compared with placebo in participants with symptomatic...

Active, not recruiting
Cardiomyopathy, Hypertrophic
Drug: Mavacamten
Other: Placebo

The primary purpose of this clinical trial is to compare the effects of study medicine (Ponsegromab/PF-06946860) with a placebo (an injection that lo...

Enrolling
Heart Failure
Drug: Open-label, PK Cohort: ponsegromab medium dose
Drug: Open-label, PK Cohort: ponsegromab low dose

The purpose of this study is to demonstrate the efficacy of 9-valent extraintestinal pathogenic Escherichia coli vaccine (ExPEC9V) compared to placeb...

Enrolling
Invasive Extraintestinal Pathogenic Escherichia Coli Disease (IED) Prevention
Biological: ExPEC9V
Other: Placebo

The purpose of this study is to compare the effectiveness of iberdomide maintenance to lenalidomide maintenance therapy after autologous stem cell tr...

Active, not recruiting
Multiple Myeloma
Drug: Lenalidomide
Drug: Iberdomide

The purpose of this study is to demonstrate that Super-Responders (SRe; defined as psoriasis participants who receive on-label guselkumab treatment u...

Active, not recruiting
Psoriasis
Drug: Guselkumab
Drug: Placebo Injection
Locations recently updated

The purpose of this study is to evaluate the efficacy of lepodisiran in reducing cardiovascular risk in participants with high lipoprotein(a) who hav...

Enrolling
Atherosclerotic Cardiovascular Disease (ASCVD)
Elevated Lp(a)
Drug: Lepodisiran Sodium
Drug: Placebo

This prospective, randomized, multicenter, open-label Phase 2 study is designed to evaluate the superiority of InO monotherapy vs ALLR3 after 1 cycle...

Enrolling
ACUTE LYMPHOBLASTIC LEUKEMIA
Drug: Inotuzumab ozogamicin
Drug: ALLR3

This study is open to adults aged 18 years and older with cystic fibrosis bronchiectasis.The purpose of this study is to find out whether a medicine...

Active, not recruiting
Bronchiectasis
Cystic Fibrosis
Drug: BI 1291583
Drug: Placebo

The primary objective of this trial is to determine if adjuvant apalutamide in prostate cancer patients at high risk of developing subsequent metasta...

Active, not recruiting
Prostatic Neoplasms
Other: Standard of care
Drug: Apalutamide 60Mg Tab

This is a phase III, randomized, double-blinded, comparative, multi-centre study to assess the efficacy of atezolizumab in combination with platinum-...

Active, not recruiting
Ovarian Cancer
Drug: placebo + avastin + platinum-based chemotherapy
Drug: atezolizumab + avastin + platinum-based chemotherapy

This is a phase III, randomized, partially blinded, multicenter trial to evaluate the efficacy and safety of atezolizumab plus bevacizumab and chemot...

Active, not recruiting
Recurrent Ovarian Carcinoma
Drug: Bevacizumab
Drug: Chemotherapy

This phase I/II clinical trial evaluates the safety and efficacy of the combined administration of midostaurin and gemtuzumab ozogamicin in the frame...

Enrolling
Acute Myeloid Leukemia
Drug: MAGMA-trial:GO associated with conventional chemotherapy (AraC+DNR)+Midostaurin
Drug: MAGNOLIA-trial: conventional chemotherapy (AraC+DNR)+GO

A Phase II study of immunotherapy with Durvalumab (MEDI4736) and Tremelimumab in combination with either Y-90 SIRT or DEB-TACE for intermediate stage...

Enrolling
Hepatocellular Carcinoma Non-resectable
HCC
Procedure: DEB-TACE
Procedure: Y-90 SIRT

This Phase 3, randomized, Double-blind, placebo-controlled, 2-arm, parallel-group, multicenter study with randomized withdrawal will evaluate the eff...

Active, not recruiting
Chronic Kidney Diseases
Drug: KBP-5074
Drug: Placebo

Trial sponsors

Boehringer Ingelheim logo
I
J
Lilly logo
U
Charité University Medicine Berlin logo
Janssen (J&J Innovative Medicine) logo
T
Abbott logo
Daiichi Sankyo logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems